Due to its superior preclinical trial performance, the next step of validation and development was undertaken, and clinical trials are currently underway for the treatment of endocrine therapy-resistant ERα+ breast cancer carrying wild-type or mutant ESR1. H3B-6545 is being evaluated in clinical phase II (NCT03250676). Here, ESR1 is linked to breast cancer.